STAMFORD, CT- 15th June, 2015- ArisGlobal®, a leading provider of software solutions to the life science industry is transforming the way license partners, distributors, patients, HCPs, sales representatives and MSLs communicate with drug and device manufacturers.
As a result of ongoing regulatory pressures all life sciences organizations are experiencing significant increases in the number of enquiries and adverse events reported annually. Collecting this data is becoming a considerable challenge and the current processes and systems are no longer scalable. Cost pressures are also placing an intolerable burden on resources.
agReporter is the new way for medical sales representatives, healthcare professionals and patients to track and report adverse events, submit medical enquiries and report product complaints from a single unified platform. Available as a web-based capture solution or as a mobile app, agReporter makes it simpler for all users to correspond with drug manufacturers and get the latest medical advice.
agReporter simplifies and streamlines two-way communication with Medical Information (MI) teams, and allows real-time sharing of relevant content – reducing wait times and relieving the pressure on overburdened MI departments.
Based on the latest technology, agReporter™ can be integrated with existing systems for complaint, adverse event and medical enquiry management but comes integrated out of the box with the ArisGlobal unified medical affairs platform consisting of agInquirer (medical information), agTracker (adverse event triage) and agResponder (complaints).
Other key benefits of agReporter™ include:
· Simplified collection of complaints, enquiries and adverse events reporting.
· Mobile optimized access and workflow for Android and iOS devices.
· Enhanced compliance in AE and PC reporting.
· Reduced paperwork and transcription data entry.
· Secure access to the latest approved global and regional product information/literature and FAQs.
Simon Sparkes, Executive Vice President Product Strategy remarked, “Like everything else, healthcare is going mobile and there are huge efficiencies to be had by enabling direct reporting and providing self-service capabilities. In clinical trials, we have seen the benefits of direct patient reporting with ePro. Life science companies can realize huge cost savings by enabling adverse event reporting at source, eliminating the inefficiencies of the current manual processes. We are taking this concept further by offering the only unified solution that allows users to also submit medical enquiries and product complaints while accessing the latest product data and FAQs. agReporter is literally a unique solution that all stakeholders can have on their iPhone, iPad or Android devices.”
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Phase III Trial Data Show Subcutaneous Pembrolizumab as Noninferior to IV Keytruda
March 31st 2025Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to intravenous Keytruda.
Phase II ALPACA Trial Shows Lepodisiran Produces Significant, Sustained Lipoprotein(a) Reductions
March 31st 2025Eli Lilly’s lepodisiran, an investigational siRNA therapy, achieved significant and durable reductions in lipoprotein(a) levels, a major genetic risk factor for cardiovascular disease.